Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma

PURPOSE: The antibody-drug conjugate glembatumumab vedotin links a fully human immunoglobulin G2 monoclonal antibody against the melanoma-related glycoprotein NMB (gpNMB) to the potent cytotoxin monomethyl auristatin E. This study evaluated the safety and activity of glembatumumab vedotin in patient...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Ott, Patrick A., Hamid, Omid, Pavlick, Anna C., Kluger, Harriet, Kim, Kevin B., Boasberg, Peter D., Simantov, Ronit, Crowley, Elizabeth, Green, Jennifer A., Hawthorne, Thomas, Davis, Thomas A., Sznol, Mario, Hwu, Patrick
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2014
Témata:
Original Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4879709/
https://ncbi.nlm.nih.gov/pubmed/25267741
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.54.8115
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky